Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 1 N=130 COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
Phase 1 N=48 Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Malaria
Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
N/A N=36 SARS-CoV-2 Human Challenge Characterisation Study
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Phase 1 N=6 Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
Healthy Volunteers
Primary: Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces — 75.2; 19.9 percentage of total radioactivity
Phase 1 N=16 Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Abnormal Physical Exam Findings — 0; 0; 0 Participants
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Phase 1 N=18 A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported
N/A N=18 Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
Malaria · Plasmodium Falciparum
Primary: Number of Participants Infected — 5; 3; 6 Participants
Phase 1 N=82 First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
Not Determined
Primary: Evaluation of Frequency, Seriousness and Intensity of Adverse Events — 7; 1; 3; 4 Adverse events
Phase 1 N=29 A Study of LY3031207 in Healthy Subjects
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE — 0; 0; 0; 0 Participants
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Phase 1 N=24 Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Covid19
Primary: Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax]) — 57.2; 41.7; 46.5; 22.3 ng/mL — p=0.803
Phase 1 N=25 Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Healthy Participants
Primary: Participant With Treatment Emergent Adverse Events (TEAEs) — 2; 3; 1 Participants
Phase 1 N=9 A GBT021601 ADME Microtracer Study in Healthy Volunteers
Sickle Cell Disease
Primary: GBT021601 Concentration in Whole Blood and Plasma at Predose — NA; NA Microgram/ milliliter (mcg/mL)
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Phase 1 N=21 Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Campylobacter Jejuni Infection
Primary: Count of Participants With Adverse Events — 0; 1; 3; 1 Participants
Phase 1 N=30 A Single Dose Study of LY3023703 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE — 0; 0; 0; 0 Participants
Phase 1 N=90 A First-in-Human Study of SBP-9330 in Healthy Subjects
Smoking Cessation
Primary: Number of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 1; 1; 1 Participants
Phase 1 N=23 RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
Covid19
Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants
Phase 1 N=24 A Safety Study of PTI-125 in Healthy Volunteers
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL